VSTM verastem.com: Enterprise Value to EBITDA Ratio

Verastem, Inc. (VSTM) is implementing laboratory automation and software robots for trial analysis. The asset-light business model involves developing inhibitors in the US while outsourcing production. A team of elite scientists is motivated by the mission and investments. The EV/EBITDA multiple for this capital-intensive enterprise on the precise GURU.Markets chart shows that the current value is 0.00.

VSTM (Verastem Oncology) Enterprise Value to Operating Income Before Depreciation Ratio history from 11/23/2025 to 11/10/2026

Comprehensive metric breakdowns and analytics for verastem.com (VSTM)

- stock price and consensus target price:

Stock Quotes Verastem Inc|VSTM - Average Forecast Price

- company stock capitalization data:

Market Valuation Verastem Corp|VSTM - Value Adjusted for Debt and Cash

- business book valuation details:

Accounting Value per Share Verastem|VSTM - Total Net Assets|Market Capitalization to Book Value Ratio verastem.com|VSTM - Company Total Assets

- debt and solvency information:

- net income and valuation multiples indicators:

VSTM - Company Net Income|Projected Future Earnings Verastem, Inc.|VSTM - Price to Earnings Multiple|Projected Price to Earnings Verastem, Inc.|VSTM - Growth-Adjusted Payback Ratio|Enterprise Value to EBITDA Ratio Verastem Corp|VSTM - Company profit before taxes, interest and amortization|Net earnings per share (EPS TTM) Verastem|VSTM - Earnings per share for the trailing year|Quarterly EPS earnings growth verastem.com|VSTM - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Verastem, Inc.

Basic company analysis:Verastem Inc VSTM

Verastem, Inc. (VSTM) development of inhibitors for specific mutations requires significant capital expenditures, making the calculation of enterprise value (EV) relative to operating profit (EBITDA) critical for analysis. The current EV/EBITDA trend for Verastem, Inc. (VSTM) allows investors to distinguish a fair premium for technological leadership in oncology from a dangerous asset overheat, thereby determining the optimal entry point for the stock.

Competitor analysis

Genmab US - Enterprise Value to EBITDA Ratio|Exelixis Inc. (EXEL) - Company Value to EBITDA|NUVL: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation KYMR (kymeratx.com)|IDYA (IDEAYA Biosciences, Inc.) - Enterprise Value to EBITDA Ratio|ELVN: Enterprise Value to Operating Income Before Depreciation Ratio|ORIC (ORIC Pharma) - EV/EBITDA Multiple|EV/EBITDA Multiple Relay Corp|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Nurix Therapeutics (NRIX)|TYRA (tyra.bio) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple GLUE (Monte Rosa Therapeutics, Inc.)|Enterprise Value to EBITDA Multiple Cullinan Oncology|Immuneering Inc. - EV/EBITDA Multiple|Company Value to EBITDA C4 Therapeutics Corp|BDTX (Black Diamond) - Enterprise Value to EBITDA Ratio|RPTX: Enterprise Value to Operating Income Before Depreciation Ratio|PMVP (PMV Pharmaceuticals, Inc.) - EV/EBITDA Multiple|Company Value to EBITDA Karyopharm KPTI|EV/EBITDA Multiple PPCB|Cyclacel - Enterprise Value to Operating Income Before Depreciation|Aadi Bioscience, Inc. - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation ALRN|BPMC: Enterprise Value to EBITDA Ratio|GlycoMimetics, Inc. - Enterprise Value to Operating Income Before Depreciation Ratio|SWTX: EV/EBITDA Multiple